Current Edition

The Devil in the Detail: Five Routine Recall Risks Faced by Modern Pharma

With the steely eyes of the regulators firmly trained on everything that life sciences organisations do, the last thing firms want is to incur fines, market delays or worse because of overlooked mistakes in labelling and product information. Growing complexity in life sciences is raising the risk of product mislabelling, potentially putting lives in danger and leaving companies open to hefty fines and delays in product availability, warns Marc Chaillou of Schlafender Hase.
http://ipimediaworld.com/wp-content/uploads/2016/12/The-devil….pdf